NEO$12.83
$12.784
Chart
Performance
Key Stats
AI NEO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldNeoGenomics shows some fundamental strengths in its niche but faces significant challenges with profitability and market position. Technical indicators suggest a downtrend, and thematic tailwinds in healthcare diagnostics are present but not currently outweighing company-specific issues. Investors should exercise caution and consider diversification.
Thematic
NeoGenomics operates in the growing field of cancer diagnostics, benefiting from advancements in molecular testing and personalized medicine. However, competition and evolving diagnostic technologies present ongoing challenges.
Fundamental
NeoGenomics exhibits mixed financial performance. While revenue has shown some growth, the company has consistently reported net losses and negative free cash flow, indicating profitability challenges and a need for significant operational improvements.
Technical
The stock is in a significant downtrend across multiple timeframes, with prices trading well below historical averages and facing strong resistance. Technical indicators overwhelmingly suggest a bearish outlook.
| Factor | Score |
|---|---|
| Healthcare Diagnostics Market Growth | 80 |
| Personalized Medicine & Genomics | 75 |
| Regulatory Environment (Healthcare) | 50 |
| Technological Disruption | 60 |
| Competition | 55 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 20 |
| Growth | 60 |
| Balance Sheet Health | 50 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 10 |
| Momentum | 30 |
| Volume Confirmation | 40 |
| Support & Resistance | 20 |
| Short-Term Indicators (15m) | 25 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprises
Recent quarterly EPS estimates have been consistently beaten, with the latest quarter (2025 Q1) showing a surprise of 36.38% (reported $0.04 vs. estimate $0.03). This indicates operational efficiency and better-than-expected profitability.
Improving Valuation Ratios
The Price-to-Sales (PS) ratio has improved from 9.1 in 2021 to 1.6 in TTM, suggesting the company is becoming more efficient at generating sales relative to its market valuation.
Bearish Points (8)
Significant Stock Decline
The stock has experienced a substantial decline over the past year (1Y performance of -57.26%) and year-to-date (YTD performance of -61.43%), indicating significant investor concerns or market challenges.
Net Losses
The company has consistently reported net losses, with TTM net income at -$58.9 million and annual net income in 2024 at -$78.7 million. This indicates ongoing profitability challenges.
Calendar
July 2025
29
Next Earnings Date
H: $0.06
A: $0.02
L: $0.01
H: 184.26M
A: 182.64M
L: 179.80M
Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Seasonals
Price Target
11.05 USD
The 39 analysts offering 1 year price forecasts for NEO have a max estimate of 15.00 and a min estimate of 8.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader and primary direct competitor in the electric vehicle market, influencing innovation and market trends for all EV manufacturers, including Nio.
Weight: 90
Direct Chinese EV competitor to Nio, vying for market share in the premium intelligent EV segment within China and increasingly globally.
Weight: 88
Direct Chinese EV competitor to Nio, focusing on extended-range electric vehicles (EREVs) and BEVs, competing for market share in China's new energy vehicle sector.
Weight: 85
Major Chinese electric vehicle and battery manufacturer; a significant competitor across various EV segments and a key player in the global EV battery supply chain.